Lead Product(s) : RZL 012
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Fosun Pharmaceutical
Deal Size : $74.0 million
Deal Type : Licensing Agreement
Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012
Details : RZL-012 is an injectable drug product indicated for aesthetic treatment of adults having moderate to significant submental fullness. Under the terms of the agreement, Raziel Therapeutics will receive potential payments between now and marketing approval ...
Product Name : RZL 012
Product Type : Other Small Molecule
Upfront Cash : $27.0 million
September 17, 2020
Lead Product(s) : RZL 012
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Fosun Pharmaceutical
Deal Size : $74.0 million
Deal Type : Licensing Agreement